All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2019-05-09T11:36:34.000Z

Ivosidenib approved as first-line treatment for AML with IDH1 mutation

May 9, 2019
Share:

Results of an open-label, multicenter, single-arm study (NCT 02074839) have led to the approval of ivosidenib for the treatment of newly diagnosed acute myeloid leukemia (AML).

On 2nd May 2019, the U.S. Food and Drug Administration (FDA) granted approval for the use of ivosidenib as the first-line therapy for newly diagnose AML with a susceptible IDH1 mutation. Patients should be at least 75 years old, or have comorbidities that preclude the use of intensive induction chemotherapy.

Patients enrolled in the study were at least 75, or had severe pulmonary or cardiac disease, creatine clearance at <45ml/min, or hepatic impairment with bilirubin >1.5 times the upper limit of normal. Ivosidenib was administered orally at 500mg once per day until progression of the disease, development of unacceptable toxicity, or hematopoietic stem cell transplantation (HSCT). Of the 28 patients enrolled in the study, the median age was 77 years (range, 64—87), and 22 (79%) had myelodysplasia-related changes or therapy-related AML.

Fatigue, diarrhea, edema, decreased appetite, leucocytosis, nausea, arthralgia, abdominal pain, dyspnea, myalgia and differentiation syndrome were the side effects seen in at least 25% of patients. As differentiation syndrome could be potentially life threatening, a boxed warning is issued with the medication to alert healthcare professionals.

The recommended dose of ivosidenib is 500mg orally, once daily with or without food, until disease progression or unacceptable toxicity. Treatment is recommended for a minimum of six months for patients without toxicity or disease progression, allowing time for clinical response.

In the study, 42.9% (n = 12) of patients achieved complete remission (CR) or CR with partial hematologic recovery (CRh).

Newsletter

Subscribe to get the best content related to AML delivered to your inbox